December 9, 2020 11:21 AM ESTUpdated December 11, 03:06 PM

Updated: News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets

Conner Mitchell

Jason Mast

Editor

More than a year after Gilead’s former R&D chief John McHutchison took the reins at Assembly Biosciences, the San Francisco, California-based company is pulling back …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets

Conner Mitchell

Jason Mast

Editor

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: News brief­ing: As­sem­bly Bio scraps mi­cro­bio­me pro­grams; In­ve­ni­AI, Ky­owa Kirin ex­pand part­ner­ship to fo­cus on nov­el tar­gets

Editor

Sign up to read this article for free.

Updated: News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets